Abstract:Background: Metabolic imbalance is the common basis of many diseases. As natural isoquinoline alkaloid, berberine (BBR) has shown great promise in regulating glucose and lipids metabolism and treating metabolic disorders. However, the related mechanism still lacks systematic research. Aim: To discuss the role of BBR in the whole body's systemic metabolic regulation and further explore its therapeutic potential and targets. Method: Based on animal and cell experiments, the mechanism of BBR regulating systemic metabolic processes is reviewed. Potential metabolism-related targets were summarized using Therapeutic Target Database (TTD), DrugBank, GeneCards, and cutting-edge literature. Molecular modeling was applied to explore BBR binding to the potential targets. Results: BBR regulates the whole-body metabolic response including digestive, circulatory, immune, endocrine, and motor systems through adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR), sirtuin (SIRT)1/forkhead box O (FOXO)1/sterol regulatory element-binding protein (SREBP)2, nuclear factor erythroid 2-related factor (Nrf) 2/heme oxygenase (HO)-1, and other signaling pathways. Through these reactions, BBR exerts hypoglycemic, lipid-regulating, anti-inflammatory, anti-oxidation, and immune regulation. Molecular docking results showed that BBR could regulate metabolism targeting FOXO3, Nrf2, NAD(P)H quinone oxidoreductase 1 (NQO1), glutathione peroxidase (Gpx) 4 and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA). Evaluating the target clinical effects, we found that BBR has the therapeutic potential of anti-aging, anti-cancer, relieving kidney disease, regulating the nervous system, and alleviating other chronic diseases. Conclusion: This review elucidates the interaction between potential targets and small molecular metabolites by exploring the mechanism of BBR regulating metabolism. That will help pharmacologists to identify new promising metabolites interacting with these targets.

Berberine is a Potential Therapeutic Agent for Metabolic Syndrome Via Brown Adipose Tissue Activation and Metabolism Regulation.

Berberine Hydrochloride Induces Brown Adipogenesis

Molecular mechanisms, targets and clinical potential of berberine in regulating metabolism: a review focussing on databases and molecular docking studies

Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence

Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans

Berberine Activates Thermogenesis in White and Brown Adipose Tissue.

Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3

A Mechanistic Review on How Berberine Use Combats Diabetes and Related Complications: Molecular, Cellular, and Metabolic Effects

Pharmacokinetics and Pharmacological Activities of Berberine in Diabetes Mellitus Treatment

Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action

Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases

Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction

Cardiovascular and metabolic effects of Berberine

Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota

Effect of Berberine on the HPA-axis Pathway and Skeletal Muscle GLUT4 in Type 2 Diabetes Mellitus Rats

Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes

Berberine attenuates obesity‐induced insulin resistance by inhibiting miR‐27a secretion

Berberine Ameliorates High-fat-induced Insulin Resistance in HepG2 Cells by Modulating PPARs Signaling Pathway

Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway

Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver